These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21978471)

  • 1. Registry initiated to characterize vision loss associated with vigabatrin therapy.
    Pellock JM; Faught E; Sergott RC; Shields WD; Burkhart GA; Krauss GL; Foroozan R; Wesche DL; Weinberg MA
    Epilepsy Behav; 2011 Dec; 22(4):710-7. PubMed ID: 21978471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
    Krauss G; Faught E; Foroozan R; Pellock JM; Sergott RC; Shields WD; Ziemann A; Dribinsky Y; Lee D; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Mar; 56():15-9. PubMed ID: 26807550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual field constriction on vigabatrin.
    Prescrire Int; 2000 Feb; 9(45):210-1. PubMed ID: 11503799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
    Sergott RC; Bittman RM; Christen EM; Sagar SM
    Epilepsy Res; 2010 Dec; 92(2-3):170-6. PubMed ID: 20951555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity.
    Lawthom C; Smith PE; Wild JM
    Ophthalmology; 2009 Mar; 116(3):565-71. PubMed ID: 19168223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual impairment in children with epilepsy treated with vigabatrin.
    Gross-Tsur V; Banin E; Shahar E; Shalev RS; Lahat E
    Ann Neurol; 2000 Jul; 48(1):60-4. PubMed ID: 10894216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vigabatrin and epilepsy: lessons learned.
    Wild JM; Ahn HS; Baulac M; Bursztyn J; Chiron C; Gandolfo E; Safran AB; Schiefer U; Perucca E
    Epilepsia; 2007 Jul; 48(7):1318-27. PubMed ID: 17635558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed, rapid visual field loss in a patient after ten years of vigabatrin therapy.
    Clayton LM; Duncan JS; Sisodiya SM; Acheson JF
    Eye (Lond); 2010 Jan; 24(1):185-6. PubMed ID: 19373265
    [No Abstract]   [Full Text] [Related]  

  • 12. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Visual field disturbances in epileptic patients treated with vigabatrin (sevril)].
    Gross-Tsur V; Lahat E; Banin E; Shahar E; Shalev R
    Harefuah; 2002 Mar; 141(3):247-9, 315. PubMed ID: 11944216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The function of eye and vision system in children and youth treated with vigabatrin--our own experiences].
    Pojda-Wilczek D; Emich-Widera E; Herba E; Pojda SM; Marszał E
    Klin Oczna; 2005; 107(10-12):654-7. PubMed ID: 16619812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity.
    Moseng L; Sæter M; Mørch-Johnsen GH; Hoff JM; Gajda A; Brodtkorb E; Midelfart A
    Acta Ophthalmol; 2011 Aug; 89(5):452-8. PubMed ID: 21251242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vigabatrin-associated visual field defects in children.
    Russell-Eggitt IM; Mackey DA; Taylor DS; Timms C; Walker JW
    Eye (Lond); 2000 Jun; 14 ( Pt 3A)():334-9. PubMed ID: 11026995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
    Tolman JA; Faulkner MA
    Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
    Prasad AN; Penney S; Buckley DJ
    Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.